{"description":"Documents matching 'tryptamine' and from Drug Enforcement Administration","count":19,"total_pages":1,"results":[{"title":"Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing five tryptamine hallucinogens, 4-hydroxy-N,N-diisopropyltryptamine (other names: 4-OH-DiPT; 3-(2-(diisopropylamino)ethyl)-1H-indol-4- ol), 5-methoxy-alpha-methyltryptamine (other names: 5-MeO-AMT; 1-(5- methoxy-1H-indol-3-yl)propan-2-amine), 5-methoxy-N-methyl-N- isopropyltryptamine (other names: 5-MeO-MiPT; N-(2-(5-methoxy-1H-indol- 3-yl)ethyl)-N-methylpropan-2-amine), 5-methoxy-N,N-diethyltryptamine (other names: 5-MeO-DET; N,N-diethyl-2-(5-methoxy-1H-indol-3- yl)ethanamine), and N,N-diisopropyltryptamine (other names: DiPT; N-(2- (1H-indol-3-yl)ethyl)-N-isopropylpropan-2-amine), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specific tryptamine hallucinogens.","document_number":"2026-19400","html_url":"https://www.federalregister.gov/documents/2026/09/23/2026-19400/schedules-of-controlled-substances-placement-of-4-hydroxy-nn-diisopropyltryptamine-4-oh-dipt","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-23/pdf/2026-19400.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19400.pdf?1790081116","publication_date":"2026-09-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"5-MeO-DET, and DiPT are part of the <span class=\"match\">tryptamine</span> family of hallucinogens and share the core <span class=\"match\">tryptamine</span> structure with substitutions at various positions. All five substances contain an indole ring with a substituted ethylamino sidechain. 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT share structural similarities with schedule I <span class=\"match\">tryptamine</span> hallucinogens such as DMT, DET, AMT, and psilocyn. \n \n Limited metabolism studies have been conducted for 5-MeO-MiPT and other <span class=\"match\">tryptamine</span> hallucinogens. Data indicate that <span class=\"match\">tryptamine</span> hallucinogens undergo metabolism"},{"title":"Importer of Controlled Substances Application: Fisher Clinical Services, Inc.","type":"Notice","abstract":"Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.","document_number":"2026-18203","html_url":"https://www.federalregister.gov/documents/2026/09/08/2026-18203/importer-of-controlled-substances-application-fisher-clinical-services-inc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-08/pdf/2026-18203.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-18203.pdf?1788525908","publication_date":"2026-09-08","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"class(es) of controlled substance(s): \n \n   \n \n Controlled substance \n Drug code \n Schedule \n \n \n Marihuana Extract \n 7350 \n I \n \n \n Marihuana \n 7360 \n I \n \n \n Tetrahydrocannabinols \n 7370 \n I \n \n \n 3,4-Methylenedioxymeth amphetamine \n 7405 \n I \n \n \n 5-Methoxy-N-N-dimethyl <span class=\"match\">tryptamine</span> \n 7431 \n I \n \n \n Dimethyltryptamine \n 7435 \n I \n \n \n Psilocybin \n 7437 \n I \n \n \n Methylphenidate \n 1724 \n II \n \n \n Levorphanol \n 9220 \n II \n \n \n Noroxymorphone \n 9668 \n II \n \n \n Tapentadol \n 9780 \n II \n \n \n The company plans to import the listed controlled substances for"},{"title":"Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I; Announcement of Hearing","type":"Proposed Rule","abstract":"This is notice that the Drug Enforcement Administration will hold a hearing with respect to the proposed placement of five tryptamine hallucinogens, as identified in the proposed rule, in schedule I of the Controlled Substances Act. The control of the five tryptamines was initially proposed in a Notice of Proposed Rulemaking published in the Federal Register on January 14, 2022.","document_number":"2022-14372","html_url":"https://www.federalregister.gov/documents/2022/07/06/2022-14372/schedules-of-controlled-substances-placement-of-4-hydroxy-nn-diisopropyltryptamine-4-oh-dipt","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14372.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-14372.pdf?1657025123","publication_date":"2022-07-06","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"ACTION: \n Notice of hearing on proposed rulemaking. \n \n \n SUMMARY: \n \n This is notice that the Drug Enforcement Administration will hold a hearing with respect to the proposed placement of five <span class=\"match\">tryptamine</span> hallucinogens, as identified in the proposed rule, in schedule I of the Controlled Substances Act. The control of the five <span class=\"match\">tryptamines</span> was initially proposed in a Notice of Proposed Rulemaking published in the \n Federal Register \n on January 14, 2022.\n \n \n \n DATES: \n Interested persons desiring to participate in this hearing must provide written"},{"title":"Exempt Chemical Preparations Under the Controlled Substances Act","type":"Notice","abstract":"The applications for exempt chemical preparations received by the Drug Enforcement Administration between April 28, 2022, and September 30, 2023, as listed below, were accepted for filing and have been approved or denied as indicated.","document_number":"2024-10465","html_url":"https://www.federalregister.gov/documents/2024/05/15/2024-10465/exempt-chemical-preparations-under-the-controlled-substances-act","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-15/pdf/2024-10465.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-10465.pdf?1715690715","publication_date":"2024-05-15","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Acetonitrile:Water [1:1] \n Glass ampoule: 1 ml \n 2/10/2023 \n \n \n Absolute Standards, Inc \n <span class=\"match\">Tryptamine</span> Mix, 100 µg/mL, in Acetonitrile:Water [1:1] \n Glass ampoule: 1 ml \n 2/10/2023 \n \n \n Absolute Standards, Inc \n <span class=\"match\">Tryptamine</span> Mix, 1000 µg/mL, in Acetonitrile:Water [1:1] \n Glass ampoule: 1 ml \n 2/10/2023 \n \n \n Absolute Standards, Inc \n <span class=\"match\">Tryptamine</span> PT, Varied µg/g, in Mushroom Matrix [Porcini Powder:Acetonitrile, 1:1] \n Glass ampoule: 1 mL \n 3/16/2023 \n \n \n Absolute Standards, Inc \n <span class=\"match\">Tryptamine</span> PT, Varied µg/mL, in Acetonitrile:Water [1:1] \n Glass ampoule: 1 ml \n 2/10/2023"},{"title":"Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I; Withdrawal of Proposed Rule and Notice of Hearing","type":"Proposed Rule","abstract":"The Drug Enforcement Administration (DEA) is withdrawing a proposed rule that was published in the Federal Register on January 14, 2022, which proposed to place five tryptamine hallucinogens in schedule I of the Controlled Substances Act. Upon further consideration, DEA has determined that it is appropriate to submit a new request to the Department of Health and Human Services (HHS) for an updated scientific and medical evaluation and scheduling recommendation for these substances. Accordingly, DEA is withdrawing the proposed rule and notice of hearing that was published in the Federal Register on July 6, 2022, and is canceling the public hearing and terminating the pending hearing proceedings. DEA may issue a new proposed rule in the future regarding these substances if warranted.","document_number":"2022-16102","html_url":"https://www.federalregister.gov/documents/2022/07/27/2022-16102/schedules-of-controlled-substances-placement-of-4-hydroxy-nn-diisopropyltryptamine-4-oh-dipt","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-07-27/pdf/2022-16102.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-16102.pdf?1658839526","publication_date":"2022-07-27","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"ACTION: \n Withdrawal of proposed rule and withdrawal of notice of hearing. \n \n \n SUMMARY: \n \n The Drug Enforcement Administration (DEA) is withdrawing a proposed rule that was published in the \n Federal Register \n on January 14, 2022, which proposed to place five <span class=\"match\">tryptamine</span> hallucinogens in schedule I of the Controlled Substances Act. Upon further consideration, DEA has determined that it is appropriate to submit a new request to the Department of Health and Human Services (HHS) for an updated scientific and medical evaluation and scheduling recommendation"},{"title":"Exempt Chemical Preparations Under the Controlled Substances Act","type":"Notice","abstract":"The applications for exempt chemical preparations received by the Drug Enforcement Administration between July 28, 2020, and December 31, 2022, as listed below, were accepted for filing and have been approved or denied as indicated.","document_number":"2023-10711","html_url":"https://www.federalregister.gov/documents/2023/05/22/2023-10711/exempt-chemical-preparations-under-the-controlled-substances-act","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-05-22/pdf/2023-10711.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-10711.pdf?1684500317","publication_date":"2023-05-22","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Mushroom Hydroxy-<span class=\"match\">Tryptamine</span> Mixture 1 mg/mL in Acetonitrile \n Glass ampule: 1 mL \n 9/17/2022 \n \n \n Cayman Chemical Company \n Mushroom Hydroxy-<span class=\"match\">Tryptamine</span> Mixture 250 µg/mL in Acetonitrile \n Glass ampule: 1 mL \n 9/17/2022 \n \n \n Cayman Chemical Company \n Mushroom Hydroxy-<span class=\"match\">Tryptamine</span> Mixture 500 µg/mL in Acetonitrile \n Glass ampule: 1 mL \n 9/17/2022 \n \n \n Cayman Chemical Company \n Mushroom Phosphorylated <span class=\"match\">Tryptamine</span> Mixture (CRM) 1 mg/mL in ACN:H20 \n Glass ampule: 1 mL \n 9/17/2022 \n \n \n Cayman Chemical Company \n Mushroom Phosphorylated <span class=\"match\">Tryptamine</span> Mixture (CRM)"},{"title":"Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing five tryptamine hallucinogens, as identified in this proposed rule, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle these five specific controlled substances.","document_number":"2022-00713","html_url":"https://www.federalregister.gov/documents/2022/01/14/2022-00713/schedules-of-controlled-substances-placement-of-4-hydroxy-nn-diisopropyltryptamine-4-oh-dipt","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-01-14/pdf/2022-00713.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-00713.pdf?1642081554","publication_date":"2022-01-14","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Other Substances \n Chemistry \n 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT are part of the <span class=\"match\">tryptamine</span> family and share the core <span class=\"match\">tryptamine</span> structure with substitutions at the α-position, 4-position, 5-position, and on the nitrogen (N) atom. All of these substances contain an indole ring with a substituted ethylamino sidechain. 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT share structural similarities with schedule I <span class=\"match\">tryptamine</span> hallucinogens such as DMT, DET, AMT, and psilocyn. \n Pharmacokinetics \n \n Metabolism studies have not"},{"title":"Bulk Manufacturer of Controlled Substances Application: Purisys, LLC","type":"Notice","abstract":"Purisys, LLC. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTAL INFORMATION listed below for further drug information.","document_number":"2022-07368","html_url":"https://www.federalregister.gov/documents/2022/04/07/2022-07368/bulk-manufacturer-of-controlled-substances-application-purisys-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-04-07/pdf/2022-07368.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-07368.pdf?1649249130","publication_date":"2022-04-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Tetrahydrocannabinols \n 7370 \n I \n \n \n 2,5-Dimethoxyamphetamine \n 7396 \n I \n \n \n \n 3,4-Methylenedioxy \n  amphetamine. \n \n 7400 \n I \n \n \n 5-Methoxy-3,4-methylenedioxy amphetamine \n 7401 \n I \n \n \n \n 3,4-Methylenedioxy \n  methamphetamine. \n \n 7405 \n I \n \n \n \n 5-Methoxy-N-N-dimethyl \n  <span class=\"match\">tryptamine</span>. \n \n 7431 \n I \n \n \n Diethyltryptamine \n 7434 \n I \n \n \n Dimethyltryptamine \n 7435 \n I \n \n \n Psilocybin \n 7437 \n I \n \n \n Psilocyn \n 7438 \n I \n \n \n Codeine-N-oxide \n 9053 \n I \n \n \n Dihydromorphine \n 9145 \n I \n \n \n Hydromorphinol \n 9301 \n I \n \n \n Morphine-N-oxide \n 9307 \n I"},{"title":"Exempt Chemical Preparations Under the Controlled Substances Act","type":"Notice","abstract":"The applications for exempt chemical preparations received by the Drug Enforcement Administration (DEA) between July 1, 2021, and December 31, 2021, as listed below, were accepted for filing and have been approved or denied as indicated.","document_number":"2022-08300","html_url":"https://www.federalregister.gov/documents/2022/04/19/2022-08300/exempt-chemical-preparations-under-the-controlled-substances-act","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-04-19/pdf/2022-08300.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-08300.pdf?1650285923","publication_date":"2022-04-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"(hydrochloride) (exempt preparation) \n Glass ampule: 0.5 mL \n 10/7/2021 \n \n \n Cayman Chemical Company \n N-methyl <span class=\"match\">Tryptamine</span> (CRM) 1 mg/mL in Acetonitrile \n Glass Ampule: 1 mL \n 9/7/2021 \n \n \n Cayman Chemical Company \n N-methyl <span class=\"match\">Tryptamine</span> (CRM) 1 mg/mL in Methanol \n Glass Ampule: 1 mL \n 9/7/2021 \n \n \n Cayman Chemical Company \n N-methyl <span class=\"match\">Tryptamine</span> (CRM) 100 μg/ml in Acetonitrile \n Glass Ampule: 1 mL \n 9/7/2021 \n \n \n Cayman Chemical Company \n N-methyl <span class=\"match\">Tryptamine</span> (CRM) 100 μg/ml in Methanol \n Glass Ampule: 1 mL \n 9/7/2021 \n \n \n Cayman Chemical Company \n ortho-Methylfentanyl"},{"title":"Technical Amendments and Corrections to DEA Regulations","type":"Rule","abstract":"This final rule updates the Code of Federal Regulations pertaining to DEA by alphabetizing definitions and eliminating the numeric listings in those definitions in order to simplify future rulemakings where additional definitions are added or deleted. This rule also corrects typographic errors, reflects organizational changes, and updates cross-reference listings in the CFR. This action makes no substantive changes to the affected rules.","document_number":"2012-1150","html_url":"https://www.federalregister.gov/documents/2012/01/27/2012-1150/technical-amendments-and-corrections-to-dea-regulations","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-01-27/pdf/2012-1150.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-01150.pdf?1327585690","publication_date":"2012-01-27","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"new chemical functionalities or destroy existing chemical functionalities, are allowed i.e., result in compounds which are positional isomers. For purposes of this definition, the “core structure” is the parent molecule that is the common basis for the class; for example, <span class=\"match\">tryptamine</span>, phenethylamine, or ergoline. Examples of rearrangements resulting in creation and/or destruction of chemical functionalities (and therefore resulting in compounds which are not positional isomers) include, but are not limited to: Ethoxy to \n alpha \n -hydroxyethyl, hydroxy"},{"title":"Definition of “Positional Isomer” as It Pertains to the Control of Schedule I Controlled Substances","type":"Rule","abstract":"On May 25, 2006, DEA published a Notice of Proposed Rulemaking which proposed the addition of a specific definition for the term \"positional isomer\" to allow for the systematic determination of which isomers of schedule I substances would be considered to be \"positional,\" and therefore, subject to schedule I control. This rulemaking finalizes that definition. The Controlled Substances Act (CSA) and its implementing regulations specify which hallucinogenic substances are considered schedule I controlled substances. The CSA states that all salts, isomers, and salts of isomers of these substances are also schedule I controlled substances. In non-technical terms, an isomer of a substance is a different compound, but a compound which has the same number and kind of atoms. The terms \"optical isomer\" and \"geometric isomer\" are specific scientific terms and it is easy to determine whether one substance is an optical or geometric isomer of another. The term \"positional isomer,\" however, is subject to scientific interpretation. The addition of a definition for the term \"positional isomer\" will assist legitimate research[ers] and industry in determining the control status of materials that are \"positional isomers\" of schedule I hallucinogens. While the DEA will remain the authority for ultimately determining the control status of a given material, providing a specific definition for \"positional isomer\" will ensure consistent criteria are utilized in making these determinations. This rule does not change existing laws, regulations, policies, processes, and procedures regarding the determination of control status for schedule I hallucinogenic substances. This rule merely makes available to the public the longstanding definition of \"positional isomer\" which DEA has used when making these scheduling determinations. This rule is relevant only to specialized forensic or research chemists. Most of these individuals are existing DEA registrants who are authorized by the DEA to handle schedule I hallucinogenic substances.","document_number":"E7-23413","html_url":"https://www.federalregister.gov/documents/2007/12/03/E7-23413/definition-of-positional-isomer-as-it-pertains-to-the-control-of-schedule-i-controlled-substances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-12-03/pdf/E7-23413.pdf","public_inspection_pdf_url":null,"publication_date":"2007-12-03","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"functionalities or destroy existing chemical functionalities, would be within the definition of positional isomer (and therefore be controlled). \n \n As clarification, note that the “core structure” is the parent molecule that is the common basis for the class; for example, <span class=\"match\">tryptamine</span>, phenethylamine, or ergoline. The following are examples of rearrangements resulting in creation and/or destruction of chemical functionalities. These rearrangements result in compounds which are not positional isomers: ethoxy to \n alpha \n -hydroxyethyl, hydroxy and methyl"},{"title":"Solicitation of Information on the Use of Tryptamine-Related Compounds","type":"Notice","abstract":"The DEA is soliciting information on substances that are related in chemical structure to tryptamine (see SUPPLEMENTARY INFORMATION). The Controlled Substances Act (CSA), in Title 21 of the United States Code (U.S.C. 812(c) Schedule I (Title 21 of the Code of Federal Regulations (CFR 1308.11(d)), lists certain tryptamines as Schedule I controlled substances. Some tryptamines that are not controlled under the CSA produce central nervous system effects that are similar to tryptamines that are controlled under the CSA. DEA is requesting information to help determine the impact on business if these substances were to be placed under control in the CSA.","document_number":"E6-12599","html_url":"https://www.federalregister.gov/documents/2006/08/04/E6-12599/solicitation-of-information-on-the-use-of-tryptamine-related-compounds","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-08-04/pdf/E6-12599.pdf","public_inspection_pdf_url":null,"publication_date":"2006-08-04","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"(1) The commercial uses for <span class=\"match\">tryptamines</span>, (2) activities involving research and development, (3) <span class=\"match\">tryptamines</span> as intermediates or analytical standards, (4) import and domestic sources for <span class=\"match\">tryptamines</span>, and (5) any planned or anticipated uses for <span class=\"match\">tryptamines</span>. DEA invites interested persons to provide any information on the uses of <span class=\"match\">tryptamines</span> in industry, academia, research and development, or other applications. Both quantitative and qualitative information is sought. \n \n Although information is requested for all <span class=\"match\">tryptamine</span> substances regardless of substitutions"},{"title":"Definition of “Positional Isomer” as It Pertains to the Control of Schedule I Controlled Substances","type":"Proposed Rule","abstract":"The Controlled Substances Act (CSA) and its implementing regulations specify which hallucinogenic substances are considered Schedule I controlled substances. The CSA states that all salts, isomers and salts of isomers of these substances are also Schedule I controlled substances. In non-technical terms, an isomer of a substance is a different compound, but a compound which has the same number and kind of atoms. The terms \"optical isomer\" and \"geometric isomer\" are specific scientific terms and it is easy to determine whether one substance is an optical or geometric isomer of another. The term \"positional isomer,\" however, is subject to scientific interpretation. This Notice of Proposed Rulemaking proposes the addition of a specific definition for the term \"positional isomer\" to allow for the systematic determination of which isomers of Schedule I substances would be considered to be \"positional\" and, therefore subject to Schedule I control. The addition of a definition for the term \"positional isomer\" will assist legitimate research and industry in determining the control status of materials that are \"positional isomers\" of Schedule I hallucinogens. While the DEA will remain the authority for ultimately determining the control status of a given material, providing a specific definition for \"positional isomer\" will ensure consistent criteria are utilized in making these determinations. This rule is relevant only to specialized forensic or research chemists. Most of these individuals are existing DEA registrants who are authorized by the DEA to handle Schedule I hallucinogenic substances.","document_number":"E6-7979","html_url":"https://www.federalregister.gov/documents/2006/05/25/E6-7979/definition-of-positional-isomer-as-it-pertains-to-the-control-of-schedule-i-controlled-substances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2006-05-25/pdf/E6-7979.pdf","public_inspection_pdf_url":null,"publication_date":"2006-05-25","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"functionalities or destroy existing chemical functionalities, would be within the definition of positional isomer (and therefore be controlled). \n \n As clarification, note that the “core structure” is the parent molecule that is the common basis for the class; for example, <span class=\"match\">tryptamine</span>, phenethylamine, or ergoline. The following are examples of rearrangements resulting in creation and/or destruction of chemical functionalities. These rearrangements result in compounds which are not positional isomers: ethoxy to \n alpha \n -hydroxyethyl, hydroxy and methyl"},{"title":"Schedules of Controlled Substances: Placement of Alpha-Methyltryptamine and 5-Methoxy-N,N-Diisopropyltryptamine Into Schedule I of the Controlled Substances Act","type":"Rule","abstract":"This final rulemaking is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to place alpha- methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO- DIPT) into Schedule I of the Controlled Substances Act (CSA). This action by the DEA Deputy Administrator is based on a scheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that AMT and 5-MeO-DIPT meet the criteria for placement in Schedule I of the CSA. This final rule will continue to impose the regulatory controls and criminal sanctions of Schedule I substances on the manufacture, distribution, and possession of AMT and 5-MeO-DIPT.","document_number":"04-21755","html_url":"https://www.federalregister.gov/documents/2004/09/29/04-21755/schedules-of-controlled-substances-placement-of-alpha-methyltryptamine-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2004-09-29/pdf/04-21755.pdf","public_inspection_pdf_url":null,"publication_date":"2004-09-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) are <span class=\"match\">tryptamine</span> (indoleethylamine) derivatives and share several similarities with the Schedule I <span class=\"match\">tryptamine</span> hallucinogens such as alpha-ethyltryptamine (AET) and N,N-dimethyltryptamine (DMT). Several other <span class=\"match\">tryptamines</span> also produce hallucinogenic/stimulant effects and are controlled as Schedule I substances under the CSA (bufotenine, diethyltryptamine, psilocybin and psilocyn). Although <span class=\"match\">tryptamine</span> itself appears to lack consistent hallucinogenic/stimulant effects, substitutions"},{"title":"Schedules of Controlled Substances: Placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine Into Schedule I of the Controlled Substances Act","type":"Proposed Rule","abstract":"The Acting Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of proposed rulemaking to place alpha-methyltryptamine (AMT) and 5-methoxy-N,N- diisopropyltryptamine (5-MeO-DIPT) into Schedule I of the Controlled Substances Act (CSA). This proposed action is based on data gathered and reviewed by the DEA. If finalized, this proposed action would continue to impose the criminal sanctions and regulatory controls of Schedule I substances under the CSA on the manufacture, distribution, and possession of AMT and 5-MeO-DIPT.","document_number":"04-7218","html_url":"https://www.federalregister.gov/documents/2004/03/31/04-7218/schedules-of-controlled-substances-placement-of-alpha-methyltryptamine-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2004-03-31/pdf/04-7218.pdf","public_inspection_pdf_url":null,"publication_date":"2004-03-31","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) are <span class=\"match\">tryptamine</span> (indoleethylamine) derivatives and share several similarities with the Schedule I <span class=\"match\">tryptamine</span> hallucinogens such as alpha-ethyltryptamine (AET) and N,N-dimethyltryptamine (DMT). Several other <span class=\"match\">tryptamines</span> also produce hallucinogenic/stimulant effects and are controlled as Schedule I substances under the CSA (bufotenine, diethyltryptamine, psilocybin and psilocyn). Although <span class=\"match\">tryptamine</span> itself appears to lack consistent hallucinogenic/stimulant effects, substitutions"},{"title":"Schedules of Controlled Substances: Temporary Placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I","type":"Rule","abstract":"The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this final rule to temporarily place alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) into Schedule I of the Controlled Substances Act (CSA) pursuant to the temporary scheduling provisions of the CSA. This final action is based on a finding by the DEA Deputy Administrator that the placement of AMT and 5-MeO-DIPT into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. As a result of this rule, the criminal sanctions and regulatory controls of Schedule I substances under the CSA will be applicable to the manufacture, distribution, and possession of AMT and 5-MeO-DIPT.","document_number":"03-8171","html_url":"https://www.federalregister.gov/documents/2003/04/04/03-8171/schedules-of-controlled-substances-temporary-placement-of-alpha-methyltryptamine-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-04-04/pdf/03-8171.pdf","public_inspection_pdf_url":null,"publication_date":"2003-04-04","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Alpha-methyltryptamine (AMT) and 5-methosy-N, N-diisopropytryptamine (5-MeO-DIPT) are <span class=\"match\">tryptamine</span> (indoleethylamine) derivatives and share several similarities with the Schedule I <span class=\"match\">tryptamine</span> hallucinogens, alpha-ethyltryptamine (AET) and N, N-demethyltryptamine (DMT), respectively. Several other <span class=\"match\">tryptamines</span> also produce hallucinogenic/stimulant effects and are controlled as Schedule I substances under the CSA (bufotenine, diethyltryptamine, psilocybin and psilocyn). Although <span class=\"match\">tryptamine</span> itself appears to lack consistent hallucinogenic/stimulant effects, substitutions"},{"title":"Schedules of Controlled Substances: Temporary Placement of Alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine Into Schedule I","type":"Proposed Rule","abstract":"The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to temporarily place alpha-methyltryptamine (AMT) and 5- methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) into Schedule I of the Controlled Substances Act (CSA) pursuant to the temporary scheduling provisions of the CSA. This intended action is based on a finding by the DEA Deputy Administrator that the placement of AMT and 5-MeO-DIPT into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Finalization of this action will impose the criminal sanctions and regulatory controls of a Schedule I substance on the manufacture, distribution, and possession of AMT and 5-MeO-DIPT.","document_number":"03-1800","html_url":"https://www.federalregister.gov/documents/2003/01/28/03-1800/schedules-of-controlled-substances-temporary-placement-of-alpha-methyltryptamine-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2003-01-28/pdf/03-1800.pdf","public_inspection_pdf_url":null,"publication_date":"2003-01-28","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) are <span class=\"match\">tryptamine</span> (indoleethylamine) derivatives and share several similarities with the Schedule I <span class=\"match\">tryptamine</span> hallucinogens, alpha-ethyltryptamine (AET) and N,N-dimethyltryptamine (DMT), respectively. Several other <span class=\"match\">tryptamines</span> also produce hallucinogenic/stimulant effects and are controlled as Schedule I substances under the CSA (bufotenine, diethyltryptamine, psilocybin and psilocin). Although <span class=\"match\">tryptamine</span> itself appears to lack consistent hallucinogenic/stimulant effects, substitutions"},{"title":"Manufacturer of Controlled Substances; Notice of Registration","type":"Notice","abstract":null,"document_number":"97-22566","html_url":"https://www.federalregister.gov/documents/1997/08/26/97-22566/manufacturer-of-controlled-substances-notice-of-registration","pdf_url":"https://www.govinfo.gov/content/pkg/FR-1997-08-26/pdf/97-22566.pdf","public_inspection_pdf_url":null,"publication_date":"1997-08-26","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"    \nAlpha-Ethyltryptamine (7249)  I                          \nLysergic acid diethylamide (7315)  I                          \n2,5-Dimethoxyamphetamine (7396)  I                          \n3,4-Methylenedioxymethampheta-mine (7405).   I                          \n Dimethyl-<span class=\"match\">tryptamine</span> (7435).                                            \n1-[1-(2-Thienyl)cyclohexyl]piperidine        I                          \n (7470).                                                                \nHeroin (9200)  I                          \nNormorphine (9313)  I       "},{"title":"Schedules of Controlled Substances; Placement of Alpha- Ethyltryptamine Into Schedule I","type":"Uncategorized Document","abstract":"This final rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to place alpha-ethyltryptamine (AET) into Schedule I of the Controlled Substances Act (CSA). This action is based on findings made by the Deputy Administrator of the DEA, after review and evaluation of the relevant data by both the DEA and the Assistant Secretary for Health, Department of Health and Human Services, that AET meets the statutory criteria for inclusion in Schedule I of the CSA. Since this substance has been temporarily placed into Schedule I, the regulatory control mechanisms and criminal sanctions of Schedule I continue to be applicable to the manufacture, distribution, importation and exportation of AET.","document_number":"94-22417","html_url":"https://www.federalregister.gov/documents/1994/09/12/94-22417/schedules-of-controlled-substances-placement-of-alpha--ethyltryptamine-into-schedule-i","pdf_url":null,"public_inspection_pdf_url":null,"publication_date":"1994-09-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opportunity \nfor interested parties to submit comments, objections or requests for a \nhearing regarding the scheduling of AET. No comments, objections or \nrequests for hearings were received regarding the scheduling of AET.\n    Alpha-ethyltryptamine has been classified as a <span class=\"match\">tryptamine</span> \nhallucinogen. Chemically it is <greek-a>-ethyl-1H-indole-3-ethanamine \nor 3-(2-aminobutyl)indole. It is structurally similar to N,N-\ndimethyltryptamine (DMT) and N,N-diethyltryptamine (DET) both of which \nare controlled in Schedule I of the CSA. Available data indicate"}]}